Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BIOPHARM GmbH
The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.
Market Intel: Expanding Applications And Improved Offerings To Drive Robotically Assisted Surgery Market
The global market for robotically assisted surgical devices will reach $11.5bn by 2025 as system improvements drive sales.
Injectable products that can alleviate pain and even reverse the disease process are on the horizon for treating degenerative orthopedic and spinal conditions, such as damaged articular joint cartilage and deteriorated spinal discs. With no available long-term treatment options for these conditions short of invasive surgical procedures like joint replacement or spinal fusion, injectable technologies that offer the possibility of being used upstream in the continuum of care are potential billion-dollar market opportunities. In fact, in a post health care reform environment, injectable therapies may prove to be the most cost-effective way for treating many degenerative conditions.
Summarizing the month in European dealmaking.
- Research, Analytical Equipment & Supplies